Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. scores highest on Torque (63) and lowest on Price (25). Its PosiPenta is 41.24 out of 100, around the middle of similar companies.
On the Penta Grid this week, Cullinan Therapeutics, Inc. is Grid #494 of 837 in the Healthcare sector in United States, and Grid #2,755 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. | 41.24 | 25 | 29 | 60 | 63 | 29 |
| Odyssey Therapeutics, Inc. | 44.57 | 29 | 32 | 51 | 57 | 53 |
| Rigel Pharmaceuticals, Inc. | 67.63 | 72 | 53 | 89 | 76 | 48 |
| Verastem, Inc. | 38.26 | 4 | 42 | 83 | 9 | 53 |
| QuidelOrtho Corporation | 40.97 | 46 | 44 | 35 | 31 | 49 |
| Aktis Oncology, Inc. | 43.03 | 31 | 26 | 30 | 68 | 60 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -4.16 |
| P/B ratio | 2.47 |
EEarnings
| Trailing EPS | ₹-294.56 |
| Forward EPS | ₹-238.31 |
NNitro
| Price | 1224.66 |
| 52-week high | 2196.44 |
| 52-week low | 637.62 |
| Fall from 52-week high | 44.2% |
TTorque
| Return on equity (ROE) | -50.30% |
| Debt-to-equity | 0.01 |
AAnchor
| Beta (price swings) | -0.04 |
| Market cap | ₹7,526 Cr |
| Insider holding | 0.42% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Cullinan Therapeutics, Inc.'s PosiPenta score?
Cullinan Therapeutics, Inc.'s PosiPenta is 41.24 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Cullinan Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Cullinan Therapeutics, Inc. is Grid #494 of 837 in the Healthcare sector in United States, and Grid #2,755 of 4,000 in United States.
Which PosiPenta pillar is strongest for Cullinan Therapeutics, Inc.?
Torque (durability), with a score of 63 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Cullinan Therapeutics, Inc.?
Price (valuation), with a score of 25 out of 100: weaker than most similar companies.
Has Cullinan Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.61 points, from 38.63 to 41.24.
PositoAI is for research and education only and is not investment advice.